Sudoscan in Patients With Autoimmune Disorders

September 12, 2015 updated by: Sun Im, The Catholic University of Korea

Investigation of Sudoscan in the Evaluation of Small Fiber Dysfunction in Korean Patients With Autoimmune Disorders

The purpose of this study is to assess the diagnostic utility of Sudoscan in assessing small fiber nerve function, specifically those of the sudomotor, in patients with autoimmune disorders (i.e fibromyalgia and rheumatoid arthritis).

Study Overview

Status

Completed

Conditions

Detailed Description

Small fiber neuropathy can manifest in different autonomic and painful symptoms, but current diagnostic tools are confined to nerve conduction studies and quantitative sensory testing.

The former can only asses the large nerve fibers and fail to reflect sudomotor function, the latter tool can be subject to technical error. Pain and autonomic dysfunction, which reflect small fiber dysfunction has recently gained much interest in disorders with polyneuropathy but current studies have been confined mostly to diabetic polyneuropathies. There has been growing evidence that autoimmune disorders such as fibromyalgia can also manifest in small fiber dysfunction. Because of the complexity of diagnosing small fiber dysfunction, there are yet no standard protocols on how to assess and treat these patients. Sudoscan uses reverse iontophoresis to assess the function of the sweat glands. The tool is easy to use, non-invasive with quantitative results that are objective.

The objective of this study is to assess the small fiber function; that is the sudomotor function; using Sudoscan in patients diagnosed with fibromyalgia and rheumatoid arthritis.

Study Type

Observational

Enrollment (Actual)

85

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bucheon, Korea, Republic of
        • Bucheon St Mary's Hospital
    • Gyenoggido
      • Bucheon, Gyenoggido, Korea, Republic of, 420-717
        • Bucheon St Mary's Hospital, Catholic University of Korea

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients who meet the following diagnostic criteria for either 1. Fibromyalgia or 2. Rheumatoid arthritis

Description

Inclusion criteria:

A. for healthy control group

- No previous diagnosis of peripheral polyneuropathy, fibromyalgia or rheumatoid arthritis

B. For case group

  • Fibromyalgia diagnosed by the rheumatology department
  • Rheumatoid arthritis diagnosed by the the rheumatology department.

Exclusion Criteria:

For control group

-Participants with previously diagnosed with medical conditions that are known to cause peripheral polyneuropathy (i.e. diabetes mellitus, chronic renal failure, hepatitis, malnutrition), or participants taking medications related to peripheral polyneuropathy(chemoagents, anti Tbc medication) or manifest with symptoms and signs of tingling sensation and gait disturbance that indicate presence of underlying peripheral polyneuropathy.

For both control and case groups

  • Severe skin deficits or swelling that may impede nerve conduction study
  • Concomitant presence of mononeuropathy of the extremities.
  • Past surgical or traumatic episodes of the foot and distal extremities subject to nerve conduction study
  • History of chronic alcoholism, of history of heavy alcohol ingestion with the last 24 hours prior o exam
  • Pregnant status at time of evaluation
  • presence of pacemaker of defibrillator
  • physical inability to lay the palms of the hand and soles of the feet on the plate electrodes.
  • scars on the palm and soles of the feet that may impair recording from the plate electrodes
  • venous insufficiency, foot swelling or foot ulceration or infection
  • Abnormal fasting glucose or Vit B12, thyroid dysfunction, Vit D and abnormal levels of lipid profile, HbA1c > 7
  • Medications with anticholinergics, TCA, anti-histamine, anti-muscarinic medication within the last 48hours
  • Patients currently taking Anti Parkinson agents, ranitidine, or other muscle relaxants, beta blockers and atropine
  • Heavy alcohol ingestion within the last 24 hour

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Control
Healthy control subjects
Fibromyalgia case group
Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
Rheumatoid arthritis group
Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sudoscan values
Time Frame: once at time of enrollment
Small fiber function from sweat glands, using Sudoscan
once at time of enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NCS studies
Time Frame: once at time of enrollment
NCS values of the upper and lower extremity sensory nerves performed by an electromyographer
once at time of enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Su-Jin Monn, M.D., PhD, Catholic University of Korea, College of Medicine Bucheon St. Mary's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Actual)

September 1, 2015

Study Completion (Actual)

September 1, 2015

Study Registration Dates

First Submitted

April 27, 2015

First Submitted That Met QC Criteria

May 4, 2015

First Posted (Estimate)

May 5, 2015

Study Record Updates

Last Update Posted (Estimate)

September 15, 2015

Last Update Submitted That Met QC Criteria

September 12, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HC15DISI0040

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autoimmune Disease

3
Subscribe